Novartis AG (NVS) 의 후행 P/E는 20.9, 선행 P/E 17.6. 후행 이익수익률은 4.79%, 선행 이익수익률 5.70%. PEG 0.93 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $63.29.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 68/100 4/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 21.6 | -0.35 | 1.94 | 2.93 | 4.47% |
| 2017 | 21.4 | 1.31 | 2.22 | 3.80 | 3.94% |
| 2018 | 13.2 | 0.20 | 2.12 | 3.61 | 4.18% |
| 2019 | 17.5 | -0.41 | 3.70 | 4.22 | 3.24% |
| 2020 | 25.2 | 1.87 | 3.60 | 4.08 | 3.43% |
| 2021 | 7.7 | 0.04 | 2.74 | 4.22 | 3.97% |
| 2022 | 26.9 | -0.38 | 3.16 | 4.31 | 4.01% |
| 2023 | 14.1 | 0.11 | 4.49 | 4.50 | 3.46% |
| 2024 | 16.4 | -0.96 | 4.46 | 3.80 | 3.88% |
| 2025 | 19.0 | 0.85 | 5.79 | 4.88 | 2.94% |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $2.80 | $49.44B | $6.71B | 13.6% |
| 2017 | $3.25 | $50.14B | $7.7B | 15.4% |
| 2018 | $5.38 | $53.17B | $12.61B | 23.7% |
| 2019 | $3.08 | $48.68B | $7.15B | 14.7% |
| 2020 | $3.52 | $49.9B | $8.07B | 16.2% |
| 2021 | $10.63 | $52.88B | $24.02B | 45.4% |
| 2022 | $3.17 | $51.83B | $6.96B | 13.4% |
| 2023 | $7.10 | $46.66B | $14.85B | 31.8% |
| 2024 | $5.87 | $51.72B | $11.94B | 23.1% |
| 2025 | $7.19 | $54.81B | $14.06B | 25.6% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $8.77 | $8.46 – $9.40 | $57.58B | $56.43B – $58.72B | 7 |
| 2027 | $9.65 | $9.28 – $10.11 | $60.71B | $58.18B – $62.6B | 7 |
| 2028 | $10.63 | $10.21 – $11.09 | $64.04B | $62.03B – $66.32B | 5 |
| 2029 | $11.47 | $11.01 – $11.96 | $66.79B | $64.69B – $69.16B | 2 |
| 2030 | $12.55 | $12.05 – $13.09 | $69.56B | $67.38B – $72.03B | 5 |
